This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Allen, J. W. Articles by Yaksh, T. L. Search for Related Content PubMed Articles by Allen, J. W. Articles by Yaksh, T. L. Related Collections Regional Anesthesia Pain Pharmacology

---

PAIN MEDICINE

An Assessment of the Antinociceptive Efficacy of Intrathecal and Epidural Contulakin-G in Rats and Dogs

From the Departments of *Anesthesiology Research, University of California, San Diego, La Jolla, California Cognetix, Inc., Salt Lake City, Utah

Address correspondence and reprint requests to Tony L. Yaksh, PhD, Anesthesiology Research, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093–0818. Address e-mail to tyaksh{at}ucsd.edu.

Contulakin-G is a novel conopeptide with an incompletely defined mechanism of action. To assess nociceptive activity we delivered Contulakin-G as a bolus intrathecally (0.03, 0.1, 0.3, 3 nmol) or epidurally (10, 30, 89 nmol) in rats. Intrathecal Contulakin G significantly decreased Phase II and, to a lesser degree, Phase I paw flinching produced by intradermal formalin. Intrathecal and epidural doses of ED50s were 0.07 nmol and 45 nmol, respectively, giving an epidural/intrathecal ED₅₀ ratio = 647). In dogs, intrathecal Contulakin-G (50-500 nmoL) produced a dose-dependent increase in the thermally evoked skin twitch latency by 30 min after administration, as did morphine (150 and 450 nmol). Epidural morphine (750 and 7500 nmol), but not epidural 1000 nmol Contulakin-G, also significantly decreased skin twitch in dogs. No changes in motor function were seen in any rats or dogs receiving these doses of Contulakin-G. In dogs, no physiologically significant dose-dependent changes in motor function, heart rate, arterial blood pressure, or body temperature were found. Contulakin-G is a potent antinociceptive drug when delivered intrathecally with no observable negative side effects in rats or dogs and may provide an alternative to opioid spinal analgesics.

This article has been cited by other articles:

				S. E. Kern, J. Allen, J. Wagstaff, S. L. Shafer, and T. Yaksh The Pharmacokinetics of the Conopeptide Contulakin-G (CGX-1160) After Intrathecal Administration: An Analysis of Data from Studies in Beagles Anesth. Analg., June 1, 2007; 104(6): 1514 - 1520. [Abstract] [Full Text] [PDF]